Home Alzheimer’s Disease FDA Grants Fast Track Designation for CLR 131 in LPL/WM

FDA Grants Fast Track Designation for CLR 131 in LPL/WM

The FDA has granted fast track designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received 2 prior treatment regimens or more, according to Cellectar Biosciences, the developer of the agent.1

CLR 131 is a small-molecule, cancer-targeting radiotherapeutic Phospholipid Drug Conjugate (PDC) designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Currently, CLR 131 is being evaluated in the company’s ongoing phase II CLOVER-1 clinical study in patients with relapsed or refractory multiple myeloma and LPL/WM.

“LPL/WM patients that do not respond optimally or are intolerant of ibrutinib, currently have limited treatment options and poor survival rates,” James Caruso, president and CEO of Cellectar, said in a press release. “Fast Track Designation for LPL/WM further…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments